Fractionated initial infusion and booster dose of ARI0002h, a humanised BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre academic pilot study

A small study of 30 patients with multiple myeloma who received ARI0002h, a BCMA-targeted CAR T-cell therapy, found deep and durable responses when ARI0002h was administered in a fractioned manner with a booster dose after 3 months. At median follow-up of 12.1 months (IQR: 9.1-13.5), 24 patients had a very good partial response or better, 9 had very good partial response, and 6 had partial response. Although no neurotoxic events were observed, 24 patients developed CRS, all at grades 1 or 2. Persistent grades 3-4 cytopenias and infections were seen in 20 patients each. One patient died due to disease progression.